Global Ofloxacin
Global Ofloxacin

Ofloxacin Comprehensive Study by Type (Oral, Intravenous Therapy (IV), Topical (Eye Drops & Ear Drops)), Application (Bronchitis, Pneumonia and Infections of the Skin, Reproductive Organs, Bladder, Urinary Tract and Prostate), Tablet Dosage (200 mg, 300 mg, 400 mg), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Tablets Shape (Oval, Oblong) Players and Region - Global Market Outlook to 2025

Ofloxacin Market Segmented into XX Submarkets. | Forecast Years: 2021- 2025  

Jan 2021 Edition 227 Pages 211 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Ofloxacin Market Overview:
The ofloxacin market is expected to grow in the future due to an increasing prevalence of infectious disease and the emergence of various mutant bacterial strains across the globe. Ofloxacin is used to treat a variety of bacterial infections. Ofloxacin belongs to a class of drugs called quinolone antibiotics. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections.

Growth Drivers
  • Growing Prevalence of Bacterial Infection due to Rising Sources of Infections
  • Increasing Need for Advanced Drugs for Treating Bacterial Infection

Market Trends
  • Increasing Research and Development Activities

Roadblocks
  • Side Effects such as Upset Stomach, Nausea, Diarrhea, Headache, Dizziness

Opportunities
  • Increasing Number of Infectious Diseases across the Globe
  • Rising Purchasing Power of Developing Countries

Challenges
  • Strict Regulation Regarding Drugs


Competitive Landscape:
The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to avail of competitive advantage through combined collaborations.
Some of the key players profiled in the report are Novartis (Switzerland), Teva Pharmaceuticals (Israel), Allergan (Ireland), Apotex (Canada), Janssen (Belgium), Daiichi Sankyo (Japan), Cadila Pharmaceuticals (India), Bestochem (India) and Almatica Pharma (United States). Analyst at AMA Research see Global Players to retain maximum share of Global Ofloxacin market by 2025. Considering Market by Tablet Dosage, the sub-segment i.e. 200 mg will boost the Ofloxacin market. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Ofloxacin market. Considering Market by Tablets Shape, the sub-segment i.e. Oval will boost the Ofloxacin market.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Ofloxacin market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Ofloxacin market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Ofloxacin Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Oral
  • Intravenous Therapy (IV)
  • Topical (Eye Drops & Ear Drops)
By Application
  • Bronchitis
  • Pneumonia and Infections of the Skin
  • Reproductive Organs
  • Bladder
  • Urinary Tract and Prostate
By Tablet Dosage
  • 200 mg
  • 300 mg
  • 400 mg

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Tablets Shape
  • Oval
  • Oblong

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Bacterial Infection due to Rising Sources of Infections
      • 3.2.2. Increasing Need for Advanced Drugs for Treating Bacterial Infection
    • 3.3. Market Challenges
      • 3.3.1. Strict Regulation Regarding Drugs
    • 3.4. Market Trends
      • 3.4.1. Increasing Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Ofloxacin, by Type, Application, Tablet Dosage, Distribution Channel, Tablets Shape and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Ofloxacin (Value)
      • 5.2.1. Global Ofloxacin by: Type (Value)
        • 5.2.1.1. Oral
        • 5.2.1.2. Intravenous Therapy (IV)
        • 5.2.1.3. Topical (Eye Drops & Ear Drops)
      • 5.2.2. Global Ofloxacin by: Application (Value)
        • 5.2.2.1. Bronchitis
        • 5.2.2.2. Pneumonia and Infections of the Skin
        • 5.2.2.3. Reproductive Organs
        • 5.2.2.4. Bladder
        • 5.2.2.5. Urinary Tract and Prostate
      • 5.2.3. Global Ofloxacin by: Tablet Dosage (Value)
        • 5.2.3.1. 200 mg
        • 5.2.3.2. 300 mg
        • 5.2.3.3. 400 mg
      • 5.2.4. Global Ofloxacin by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Online Pharmacies
      • 5.2.5. Global Ofloxacin by: Tablets Shape (Value)
        • 5.2.5.1. Oval
        • 5.2.5.2. Oblong
      • 5.2.6. Global Ofloxacin Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Ofloxacin (Price)
      • 5.3.1. Global Ofloxacin by: Type (Price)
  • 6. Ofloxacin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Teva Pharmaceuticals (Israel)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Allergan (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Apotex (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Janssen (Belgium)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Daiichi Sankyo (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cadila Pharmaceuticals (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bestochem (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Almatica Pharma (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Ofloxacin Sale, by Type, Application, Tablet Dosage, Distribution Channel, Tablets Shape and Region (value and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Ofloxacin (Value)
      • 7.2.1. Global Ofloxacin by: Type (Value)
        • 7.2.1.1. Oral
        • 7.2.1.2. Intravenous Therapy (IV)
        • 7.2.1.3. Topical (Eye Drops & Ear Drops)
      • 7.2.2. Global Ofloxacin by: Application (Value)
        • 7.2.2.1. Bronchitis
        • 7.2.2.2. Pneumonia and Infections of the Skin
        • 7.2.2.3. Reproductive Organs
        • 7.2.2.4. Bladder
        • 7.2.2.5. Urinary Tract and Prostate
      • 7.2.3. Global Ofloxacin by: Tablet Dosage (Value)
        • 7.2.3.1. 200 mg
        • 7.2.3.2. 300 mg
        • 7.2.3.3. 400 mg
      • 7.2.4. Global Ofloxacin by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Online Pharmacies
      • 7.2.5. Global Ofloxacin by: Tablets Shape (Value)
        • 7.2.5.1. Oval
        • 7.2.5.2. Oblong
      • 7.2.6. Global Ofloxacin Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Ofloxacin (Price)
      • 7.3.1. Global Ofloxacin by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Ofloxacin: by Type(USD Million)
  • Table 2. Ofloxacin Oral , by Region USD Million (2015-2020)
  • Table 3. Ofloxacin Intravenous Therapy (IV) , by Region USD Million (2015-2020)
  • Table 4. Ofloxacin Topical (Eye Drops & Ear Drops) , by Region USD Million (2015-2020)
  • Table 5. Ofloxacin: by Application(USD Million)
  • Table 6. Ofloxacin Bronchitis , by Region USD Million (2015-2020)
  • Table 7. Ofloxacin Pneumonia and Infections of the Skin , by Region USD Million (2015-2020)
  • Table 8. Ofloxacin Reproductive Organs , by Region USD Million (2015-2020)
  • Table 9. Ofloxacin Bladder , by Region USD Million (2015-2020)
  • Table 10. Ofloxacin Urinary Tract and Prostate , by Region USD Million (2015-2020)
  • Table 11. Ofloxacin: by Tablet Dosage(USD Million)
  • Figure 6. Global Ofloxacin: by Tablet Dosage USD Million (2015-2020)
  • Table 12. Ofloxacin 200 mg , by Region USD Million (2015-2020)
  • Table 13. Ofloxacin 300 mg , by Region USD Million (2015-2020)
  • Table 14. Ofloxacin 400 mg , by Region USD Million (2015-2020)
  • Table 15. Ofloxacin: by Distribution Channel(USD Million)
  • Table 16. Ofloxacin Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 17. Ofloxacin Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 18. Ofloxacin Online Pharmacies , by Region USD Million (2015-2020)
  • Table 19. Ofloxacin: by Tablets Shape(USD Million)
  • Figure 8. Global Ofloxacin: by Tablets Shape USD Million (2015-2020)
  • Table 20. Ofloxacin Oval , by Region USD Million (2015-2020)
  • Table 21. Ofloxacin Oblong , by Region USD Million (2015-2020)
  • Table 22. South America Ofloxacin, by Country USD Million (2015-2020)
  • Table 23. South America Ofloxacin, by Type USD Million (2015-2020)
  • Table 24. South America Ofloxacin, by Application USD Million (2015-2020)
  • Table 25. South America Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 26. South America Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 27. South America Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 28. Brazil Ofloxacin, by Type USD Million (2015-2020)
  • Table 29. Brazil Ofloxacin, by Application USD Million (2015-2020)
  • Table 30. Brazil Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 31. Brazil Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 32. Brazil Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 33. Argentina Ofloxacin, by Type USD Million (2015-2020)
  • Table 34. Argentina Ofloxacin, by Application USD Million (2015-2020)
  • Table 35. Argentina Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 36. Argentina Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 37. Argentina Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 38. Rest of South America Ofloxacin, by Type USD Million (2015-2020)
  • Table 39. Rest of South America Ofloxacin, by Application USD Million (2015-2020)
  • Table 40. Rest of South America Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 41. Rest of South America Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 42. Rest of South America Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 43. Asia Pacific Ofloxacin, by Country USD Million (2015-2020)
  • Table 44. Asia Pacific Ofloxacin, by Type USD Million (2015-2020)
  • Table 45. Asia Pacific Ofloxacin, by Application USD Million (2015-2020)
  • Table 46. Asia Pacific Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 47. Asia Pacific Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 48. Asia Pacific Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 49. China Ofloxacin, by Type USD Million (2015-2020)
  • Table 50. China Ofloxacin, by Application USD Million (2015-2020)
  • Table 51. China Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 52. China Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 53. China Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 54. Japan Ofloxacin, by Type USD Million (2015-2020)
  • Table 55. Japan Ofloxacin, by Application USD Million (2015-2020)
  • Table 56. Japan Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 57. Japan Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 58. Japan Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 59. India Ofloxacin, by Type USD Million (2015-2020)
  • Table 60. India Ofloxacin, by Application USD Million (2015-2020)
  • Table 61. India Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 62. India Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 63. India Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 64. South Korea Ofloxacin, by Type USD Million (2015-2020)
  • Table 65. South Korea Ofloxacin, by Application USD Million (2015-2020)
  • Table 66. South Korea Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 67. South Korea Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 68. South Korea Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 69. Taiwan Ofloxacin, by Type USD Million (2015-2020)
  • Table 70. Taiwan Ofloxacin, by Application USD Million (2015-2020)
  • Table 71. Taiwan Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 72. Taiwan Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 73. Taiwan Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 74. Australia Ofloxacin, by Type USD Million (2015-2020)
  • Table 75. Australia Ofloxacin, by Application USD Million (2015-2020)
  • Table 76. Australia Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 77. Australia Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 78. Australia Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 79. Rest of Asia-Pacific Ofloxacin, by Type USD Million (2015-2020)
  • Table 80. Rest of Asia-Pacific Ofloxacin, by Application USD Million (2015-2020)
  • Table 81. Rest of Asia-Pacific Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 82. Rest of Asia-Pacific Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 83. Rest of Asia-Pacific Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 84. Europe Ofloxacin, by Country USD Million (2015-2020)
  • Table 85. Europe Ofloxacin, by Type USD Million (2015-2020)
  • Table 86. Europe Ofloxacin, by Application USD Million (2015-2020)
  • Table 87. Europe Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 88. Europe Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 89. Europe Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 90. Germany Ofloxacin, by Type USD Million (2015-2020)
  • Table 91. Germany Ofloxacin, by Application USD Million (2015-2020)
  • Table 92. Germany Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 93. Germany Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 94. Germany Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 95. France Ofloxacin, by Type USD Million (2015-2020)
  • Table 96. France Ofloxacin, by Application USD Million (2015-2020)
  • Table 97. France Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 98. France Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 99. France Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 100. Italy Ofloxacin, by Type USD Million (2015-2020)
  • Table 101. Italy Ofloxacin, by Application USD Million (2015-2020)
  • Table 102. Italy Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 103. Italy Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 104. Italy Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 105. United Kingdom Ofloxacin, by Type USD Million (2015-2020)
  • Table 106. United Kingdom Ofloxacin, by Application USD Million (2015-2020)
  • Table 107. United Kingdom Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 108. United Kingdom Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 109. United Kingdom Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 110. Netherlands Ofloxacin, by Type USD Million (2015-2020)
  • Table 111. Netherlands Ofloxacin, by Application USD Million (2015-2020)
  • Table 112. Netherlands Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 113. Netherlands Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 114. Netherlands Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 115. Rest of Europe Ofloxacin, by Type USD Million (2015-2020)
  • Table 116. Rest of Europe Ofloxacin, by Application USD Million (2015-2020)
  • Table 117. Rest of Europe Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 118. Rest of Europe Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 119. Rest of Europe Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 120. MEA Ofloxacin, by Country USD Million (2015-2020)
  • Table 121. MEA Ofloxacin, by Type USD Million (2015-2020)
  • Table 122. MEA Ofloxacin, by Application USD Million (2015-2020)
  • Table 123. MEA Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 124. MEA Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 125. MEA Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 126. Middle East Ofloxacin, by Type USD Million (2015-2020)
  • Table 127. Middle East Ofloxacin, by Application USD Million (2015-2020)
  • Table 128. Middle East Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 129. Middle East Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 130. Middle East Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 131. Africa Ofloxacin, by Type USD Million (2015-2020)
  • Table 132. Africa Ofloxacin, by Application USD Million (2015-2020)
  • Table 133. Africa Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 134. Africa Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 135. Africa Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 136. North America Ofloxacin, by Country USD Million (2015-2020)
  • Table 137. North America Ofloxacin, by Type USD Million (2015-2020)
  • Table 138. North America Ofloxacin, by Application USD Million (2015-2020)
  • Table 139. North America Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 140. North America Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 141. North America Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 142. United States Ofloxacin, by Type USD Million (2015-2020)
  • Table 143. United States Ofloxacin, by Application USD Million (2015-2020)
  • Table 144. United States Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 145. United States Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 146. United States Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 147. Canada Ofloxacin, by Type USD Million (2015-2020)
  • Table 148. Canada Ofloxacin, by Application USD Million (2015-2020)
  • Table 149. Canada Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 150. Canada Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 151. Canada Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 152. Mexico Ofloxacin, by Type USD Million (2015-2020)
  • Table 153. Mexico Ofloxacin, by Application USD Million (2015-2020)
  • Table 154. Mexico Ofloxacin, by Tablet Dosage USD Million (2015-2020)
  • Table 155. Mexico Ofloxacin, by Distribution Channel USD Million (2015-2020)
  • Table 156. Mexico Ofloxacin, by Tablets Shape USD Million (2015-2020)
  • Table 157. Ofloxacin: by Type(USD/Units)
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Ofloxacin: by Type(USD Million)
  • Table 168. Ofloxacin Oral , by Region USD Million (2020-2025)
  • Table 169. Ofloxacin Intravenous Therapy (IV) , by Region USD Million (2020-2025)
  • Table 170. Ofloxacin Topical (Eye Drops & Ear Drops) , by Region USD Million (2020-2025)
  • Table 171. Ofloxacin: by Application(USD Million)
  • Table 172. Ofloxacin Bronchitis , by Region USD Million (2020-2025)
  • Table 173. Ofloxacin Pneumonia and Infections of the Skin , by Region USD Million (2020-2025)
  • Table 174. Ofloxacin Reproductive Organs , by Region USD Million (2020-2025)
  • Table 175. Ofloxacin Bladder , by Region USD Million (2020-2025)
  • Table 176. Ofloxacin Urinary Tract and Prostate , by Region USD Million (2020-2025)
  • Table 177. Ofloxacin: by Tablet Dosage(USD Million)
  • Figure 39. Global Ofloxacin: by Tablet Dosage USD Million (2020-2025)
  • Table 178. Ofloxacin 200 mg , by Region USD Million (2020-2025)
  • Table 179. Ofloxacin 300 mg , by Region USD Million (2020-2025)
  • Table 180. Ofloxacin 400 mg , by Region USD Million (2020-2025)
  • Table 181. Ofloxacin: by Distribution Channel(USD Million)
  • Table 182. Ofloxacin Hospital Pharmacies , by Region USD Million (2020-2025)
  • Table 183. Ofloxacin Retail Pharmacies , by Region USD Million (2020-2025)
  • Table 184. Ofloxacin Online Pharmacies , by Region USD Million (2020-2025)
  • Table 185. Ofloxacin: by Tablets Shape(USD Million)
  • Figure 41. Global Ofloxacin: by Tablets Shape USD Million (2020-2025)
  • Table 186. Ofloxacin Oval , by Region USD Million (2020-2025)
  • Table 187. Ofloxacin Oblong , by Region USD Million (2020-2025)
  • Table 188. South America Ofloxacin, by Country USD Million (2020-2025)
  • Table 189. South America Ofloxacin, by Type USD Million (2020-2025)
  • Table 190. South America Ofloxacin, by Application USD Million (2020-2025)
  • Table 191. South America Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 192. South America Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 193. South America Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 194. Brazil Ofloxacin, by Type USD Million (2020-2025)
  • Table 195. Brazil Ofloxacin, by Application USD Million (2020-2025)
  • Table 196. Brazil Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 197. Brazil Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 198. Brazil Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 199. Argentina Ofloxacin, by Type USD Million (2020-2025)
  • Table 200. Argentina Ofloxacin, by Application USD Million (2020-2025)
  • Table 201. Argentina Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 202. Argentina Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 203. Argentina Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 204. Rest of South America Ofloxacin, by Type USD Million (2020-2025)
  • Table 205. Rest of South America Ofloxacin, by Application USD Million (2020-2025)
  • Table 206. Rest of South America Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 207. Rest of South America Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 208. Rest of South America Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 209. Asia Pacific Ofloxacin, by Country USD Million (2020-2025)
  • Table 210. Asia Pacific Ofloxacin, by Type USD Million (2020-2025)
  • Table 211. Asia Pacific Ofloxacin, by Application USD Million (2020-2025)
  • Table 212. Asia Pacific Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 213. Asia Pacific Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 214. Asia Pacific Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 215. China Ofloxacin, by Type USD Million (2020-2025)
  • Table 216. China Ofloxacin, by Application USD Million (2020-2025)
  • Table 217. China Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 218. China Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 219. China Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 220. Japan Ofloxacin, by Type USD Million (2020-2025)
  • Table 221. Japan Ofloxacin, by Application USD Million (2020-2025)
  • Table 222. Japan Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 223. Japan Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 224. Japan Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 225. India Ofloxacin, by Type USD Million (2020-2025)
  • Table 226. India Ofloxacin, by Application USD Million (2020-2025)
  • Table 227. India Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 228. India Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 229. India Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 230. South Korea Ofloxacin, by Type USD Million (2020-2025)
  • Table 231. South Korea Ofloxacin, by Application USD Million (2020-2025)
  • Table 232. South Korea Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 233. South Korea Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 234. South Korea Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 235. Taiwan Ofloxacin, by Type USD Million (2020-2025)
  • Table 236. Taiwan Ofloxacin, by Application USD Million (2020-2025)
  • Table 237. Taiwan Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 238. Taiwan Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 239. Taiwan Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 240. Australia Ofloxacin, by Type USD Million (2020-2025)
  • Table 241. Australia Ofloxacin, by Application USD Million (2020-2025)
  • Table 242. Australia Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 243. Australia Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 244. Australia Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 245. Rest of Asia-Pacific Ofloxacin, by Type USD Million (2020-2025)
  • Table 246. Rest of Asia-Pacific Ofloxacin, by Application USD Million (2020-2025)
  • Table 247. Rest of Asia-Pacific Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 248. Rest of Asia-Pacific Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 249. Rest of Asia-Pacific Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 250. Europe Ofloxacin, by Country USD Million (2020-2025)
  • Table 251. Europe Ofloxacin, by Type USD Million (2020-2025)
  • Table 252. Europe Ofloxacin, by Application USD Million (2020-2025)
  • Table 253. Europe Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 254. Europe Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 255. Europe Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 256. Germany Ofloxacin, by Type USD Million (2020-2025)
  • Table 257. Germany Ofloxacin, by Application USD Million (2020-2025)
  • Table 258. Germany Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 259. Germany Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 260. Germany Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 261. France Ofloxacin, by Type USD Million (2020-2025)
  • Table 262. France Ofloxacin, by Application USD Million (2020-2025)
  • Table 263. France Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 264. France Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 265. France Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 266. Italy Ofloxacin, by Type USD Million (2020-2025)
  • Table 267. Italy Ofloxacin, by Application USD Million (2020-2025)
  • Table 268. Italy Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 269. Italy Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 270. Italy Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 271. United Kingdom Ofloxacin, by Type USD Million (2020-2025)
  • Table 272. United Kingdom Ofloxacin, by Application USD Million (2020-2025)
  • Table 273. United Kingdom Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 274. United Kingdom Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 275. United Kingdom Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 276. Netherlands Ofloxacin, by Type USD Million (2020-2025)
  • Table 277. Netherlands Ofloxacin, by Application USD Million (2020-2025)
  • Table 278. Netherlands Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 279. Netherlands Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 280. Netherlands Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 281. Rest of Europe Ofloxacin, by Type USD Million (2020-2025)
  • Table 282. Rest of Europe Ofloxacin, by Application USD Million (2020-2025)
  • Table 283. Rest of Europe Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 284. Rest of Europe Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 285. Rest of Europe Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 286. MEA Ofloxacin, by Country USD Million (2020-2025)
  • Table 287. MEA Ofloxacin, by Type USD Million (2020-2025)
  • Table 288. MEA Ofloxacin, by Application USD Million (2020-2025)
  • Table 289. MEA Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 290. MEA Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 291. MEA Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 292. Middle East Ofloxacin, by Type USD Million (2020-2025)
  • Table 293. Middle East Ofloxacin, by Application USD Million (2020-2025)
  • Table 294. Middle East Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 295. Middle East Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 296. Middle East Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 297. Africa Ofloxacin, by Type USD Million (2020-2025)
  • Table 298. Africa Ofloxacin, by Application USD Million (2020-2025)
  • Table 299. Africa Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 300. Africa Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 301. Africa Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 302. North America Ofloxacin, by Country USD Million (2020-2025)
  • Table 303. North America Ofloxacin, by Type USD Million (2020-2025)
  • Table 304. North America Ofloxacin, by Application USD Million (2020-2025)
  • Table 305. North America Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 306. North America Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 307. North America Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 308. United States Ofloxacin, by Type USD Million (2020-2025)
  • Table 309. United States Ofloxacin, by Application USD Million (2020-2025)
  • Table 310. United States Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 311. United States Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 312. United States Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 313. Canada Ofloxacin, by Type USD Million (2020-2025)
  • Table 314. Canada Ofloxacin, by Application USD Million (2020-2025)
  • Table 315. Canada Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 316. Canada Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 317. Canada Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 318. Mexico Ofloxacin, by Type USD Million (2020-2025)
  • Table 319. Mexico Ofloxacin, by Application USD Million (2020-2025)
  • Table 320. Mexico Ofloxacin, by Tablet Dosage USD Million (2020-2025)
  • Table 321. Mexico Ofloxacin, by Distribution Channel USD Million (2020-2025)
  • Table 322. Mexico Ofloxacin, by Tablets Shape USD Million (2020-2025)
  • Table 323. Ofloxacin: by Type(USD/Units)
  • Table 324. Research Programs/Design for This Report
  • Table 325. Key Data Information from Secondary Sources
  • Table 326. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Ofloxacin: by Type USD Million (2015-2020)
  • Figure 5. Global Ofloxacin: by Application USD Million (2015-2020)
  • Figure 7. Global Ofloxacin: by Distribution Channel USD Million (2015-2020)
  • Figure 9. South America Ofloxacin Share (%), by Country
  • Figure 10. Asia Pacific Ofloxacin Share (%), by Country
  • Figure 11. Europe Ofloxacin Share (%), by Country
  • Figure 12. MEA Ofloxacin Share (%), by Country
  • Figure 13. North America Ofloxacin Share (%), by Country
  • Figure 14. Global Ofloxacin: by Type USD/Units (2015-2020)
  • Figure 15. Global Ofloxacin share by Players 2020 (%)
  • Figure 16. Global Ofloxacin share by Players (Top 3) 2020(%)
  • Figure 17. Global Ofloxacin share by Players (Top 5) 2020(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 21. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 22. Teva Pharmaceuticals (Israel) Revenue: by Geography 2020
  • Figure 23. Allergan (Ireland) Revenue, Net Income and Gross profit
  • Figure 24. Allergan (Ireland) Revenue: by Geography 2020
  • Figure 25. Apotex (Canada) Revenue, Net Income and Gross profit
  • Figure 26. Apotex (Canada) Revenue: by Geography 2020
  • Figure 27. Janssen (Belgium) Revenue, Net Income and Gross profit
  • Figure 28. Janssen (Belgium) Revenue: by Geography 2020
  • Figure 29. Daiichi Sankyo (Japan) Revenue, Net Income and Gross profit
  • Figure 30. Daiichi Sankyo (Japan) Revenue: by Geography 2020
  • Figure 31. Cadila Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 32. Cadila Pharmaceuticals (India) Revenue: by Geography 2020
  • Figure 33. Bestochem (India) Revenue, Net Income and Gross profit
  • Figure 34. Bestochem (India) Revenue: by Geography 2020
  • Figure 35. Almatica Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 36. Almatica Pharma (United States) Revenue: by Geography 2020
  • Figure 37. Global Ofloxacin: by Type USD Million (2020-2025)
  • Figure 38. Global Ofloxacin: by Application USD Million (2020-2025)
  • Figure 40. Global Ofloxacin: by Distribution Channel USD Million (2020-2025)
  • Figure 42. South America Ofloxacin Share (%), by Country
  • Figure 43. Asia Pacific Ofloxacin Share (%), by Country
  • Figure 44. Europe Ofloxacin Share (%), by Country
  • Figure 45. MEA Ofloxacin Share (%), by Country
  • Figure 46. North America Ofloxacin Share (%), by Country
  • Figure 47. Global Ofloxacin: by Type USD/Units (2020-2025)
Some of the key companies/manufacturers profiled in the report
  • Novartis (Switzerland)
  • Teva Pharmaceuticals (Israel)
  • Allergan (Ireland)
  • Apotex (Canada)
  • Janssen (Belgium)
  • Daiichi Sankyo (Japan)
  • Cadila Pharmaceuticals (India)
  • Bestochem (India)
  • Almatica Pharma (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation